Return to Cardiovascular Business Alert Section
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
December 17th, 2007
2007 DEC 17 -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies. In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease. "Recent changes to the American Diabetes Association guidelines highlight the diabetic's increased risk for coronary artery disease (CAD)," according to MedPredict's President Jeff Berk. "In light of these guidelines, our Panel provides insight into unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)." Keywords: Cardiology, Cardiovascular Disease, Diabetes, Endocrinology, Pharmaceuticals, Therapy, Treatment, MedPredict. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
Return to Cardiovascular Business Alert Section
|
